Next Article in Journal
CARI III Inhibits Tumor Growth in a Melanoma-Bearing Mouse Model through Induction of G0/G1 Cell Cycle Arrest
Next Article in Special Issue
Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
Previous Article in Journal
Three Novel Lanthanide Metal-Organic Frameworks (Ln-MOFs) Constructed by Unsymmetrical Aromatic Dicarboxylatic Tectonics: Synthesis, Crystal Structures and Luminescent Properties
Previous Article in Special Issue
Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance
Article Menu

Export Article

Open AccessReview
Molecules 2014, 19(9), 14366-14382; doi:10.3390/molecules190914366

Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey

1
Institut Curie, UMR CNRS 176, 26 rue d'Ulm, Paris 75005, France
2
Faculté de Pharmacie de Paris, Université Paris Descartes, UMR CNRS 8638, 4 avenue de l'Observatoire, Paris 75006, France
*
Author to whom correspondence should be addressed.
Received: 25 July 2014 / Revised: 26 August 2014 / Accepted: 28 August 2014 / Published: 11 September 2014
(This article belongs to the Special Issue Design and Study of Kinase Inhibitors)
View Full-Text   |   Download PDF [938 KB, uploaded 12 September 2014]   |  

Abstract

In the early 2000s, the anticancer drug imatinib (Glivec®) appeared on the market, exhibiting a new mode of action by selective kinase inhibition. Consequently, kinases became a validated therapeutic target, paving the way for further developments. Although these kinases have been thoroughly studied, none of the compounds commercialized since then target cyclin-dependent kinases (CDKs). Following a recent and detailed review on the subject by Galons et al., we concentrate our attention on an updated list of compounds under clinical evaluation (phase I/II/III) and discuss their mode of action as ATP-competitive inhibitors. CDK inhibition profiles and clinical development stages are reported for the 14 compounds under clinical evaluation. Also, tentative progress for forthcoming potential ATP non-competitive inhibitors and allosteric inhibitors are briefly described, along with their limitations. View Full-Text
Keywords: CDK; kinase; inhibitor; anticancer; heterocycle; clinical evaluation; ATP-competitive; allosteric site; ATP non-competitive CDK; kinase; inhibitor; anticancer; heterocycle; clinical evaluation; ATP-competitive; allosteric site; ATP non-competitive
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Mariaule, G.; Belmont, P. Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey. Molecules 2014, 19, 14366-14382.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top